PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Colin Andrew Leach	01/29/2007

RECEIVING PARTY DATA

Name:	SmithKline Beecham Corporation	
Street Address:	One Franklin Plaza	
Internal Address:	PO Box 7929	
City:	Philadelphia	
State/Country:	PENNSYLVANIA	
Postal Code:	19101	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	11626882

CORRESPONDENCE DATA

Fax Number: (610)270-5253

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 610-270-5014

Email: US_CIPKOP@GSK.com

Correspondent Name: GlaxoSmithKline
Address Line 1: 709 Swedeland Road

Address Line 2: UW2220

Address Line 4: King of Prussia, PENNSYLVANIA 19406

ATTORNEY DOCKET NUMBER:	PU62176
NAME OF SUBMITTER:	James M. Kanagy

Total Attachments: 2

500215784

source=Assignment#page1.tif source=Assignment#page2.tif

PATENT

REEL: 018829 FRAME: 0651

√H \$40.00

Docket No.: PU61726

ASSIGNMENT

WHEREAS I, Colin Andrew LEACH of King of Prussia, PA USA, a citizen of Great Britian; have made an invention entitled:

"Bicyclic Heteroaromatic Compounds"

for which on an even date I executed an application for Letters Patent of the United States under 35 U.S.C. §111(a), executed an application for Letters Patents of the United States under 35 U.S.C. §371, or filed a Provisional application under 35 U.S.C. §111(b):

NOW, THEREFORE, in return for valuable consideration paid to me by SmithKline Beecham Corporation, a corporation organized under the laws of the Commonwealth of Pennsylvania and having its principal place of business at One Franklin Plaza, PO Box 7929 Philadelphia, Pennsylvania 19101, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, I do hereby assign unto the said SmithKline Beecham Corporation, its successors and assigns, the entire right, title and interest in and to the said invention, executed under 35 U.S.C. §111(a), 35 U.S.C. §371, or filed under 35 U.S.C. §111(b) application, and from which priority may be claimed from one or more 35 U.S.C. §111(b) applications, or any division, continuation and continuation-in-part of said application, and all Letters Patent of the United States and all foreign countries to be obtained therefor;

I further assign to the said SmithKline Beecham Corporation the right, optionally in its own name or in the names of its related companies, to apply for, obtain and maintain in all countries foreign to the United States, patent and/or Utility Model applications for said invention, including the full right to claim for any such application the benefits of any priority rights based on said executed United States application;

And I agree to execute further instruments (including provisional, divisional, continuation, continuation-in-part or reissue applications or other instruments) proper to effectuate the premises, this agreement to be binding upon my heirs, executors and administrators;

And I request the Commissioner of Patents and Trademarks of the United States, and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue Letters Patent in accordance herewith.

Colin Andrew LEACH

Date: 29-Jan-07

PATENT

REEL: 018829 FRAME: 0652

PLEASE ACKNOWLEDGE YOUR UNDERSTANDING OF THIS DOCUMENT BY SIGNING THIS SHEET WHERE INDICATED BELOW AND RETURN IT TO ME.

To: Colin Andrew LEACH

From: James M Kanagy

PU62176 Re:

EXECUTION OF APPLICATION FOR UNITED STATES PATENT

Enclosed is an application for United States patent including a Declaration and Power of Attorney for your signature which is required by the United States Patent and Trademark Office. The statements in the Declaration include the following:

- you believe that you are the first inventor or joint inventor of the claimed invention; (a)
- you have reviewed and understand the contents of the patent application; and (b)
- (c) you acknowledge the duty to disclose information material to the patentability of the invention.

Further, it is a requirement under the law and the Rules of the Patent and Trademark Office that the "best mode" for carrying out the invention known to you at the present time must be disclosed. For example, for a new series of compounds, the best route of synthesis which you know of must be disclosed. Any biological data should be a fair representation of all the data obtained to date.

Please review the specification, claims, and declaration carefully, keeping in mind your obligations as set forth above. The statements and descriptions in the specification should be true and accurate to the best of your knowledge. Generally, minor typographical errors can be corrected by amendment after filing the application. Any other errors or omissions you might find should be discussed with me by telephone prior to executing the application. Do not make any marks on the application. Once you are satisfied that the entire application is accurate and complete, please sign and date the Declaration and return the signed and dated Declaration and the accompanying specification to me.

If any material references or chemical or biological data relating to this application are available to you which have not been communicated to me, please do so immediately.

If you have any questions, please contact the indicated attorney or agent. Andrew Lease 29-Jan-07
date

RECORDED: 01/31/2007

PATENT REEL: 018829 FRAME: 0653